|
    AMLX U.S.: Nasdaq

    Amylyx Pharmaceuticals Inc.

    AMLXUS
    After Hours
    Last Updated: Sep 9, 2022 7:54 p.m. EDT Delayed quote

    $ 30.48

    0.60 2.01%
    After Hours Volume: 8.64K
    Close Chg Chg %
    $29.88 2.85 10.54%
    Advanced Charting
    Volume: 4.3M 65 Day Avg: 1.11M
    385% vs Avg
    27.30 Day Range 31.84
    6.51 52 Week Range 33.41

    Your Watchlists

    Customize MarketWatch

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    No Saved Watchlists

    Create a list of the investments you want to track.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    AMLX Overview

    Key Data

    • Open $27.40
    • Day Range 27.30 - 31.84
    • 52 Week Range 6.51 - 33.41
    • Market Cap $1.58B
    • Shares Outstanding 58.53M
    • Public Float 30.48M
    • Beta 1.20
    • Rev. per Employee $1,390.24
    • P/E Ratio N/A
    • EPS -$2.62
    • Yield N/A
    • Dividend N/A
    • Ex-Dividend Date N/A
    • Short Interest 3.4M 08/15/22
    • % of Float Shorted 11.17%
    • Average Volume 1.11M

    Performance

    5 Day
    • 65.27%
    1 Month
    • 19.23%
    3 Month
    • 120.84%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 5 Full Ratings

    Recent News

    Read full story

    Amylyx ALS Drug Wins Backing of FDA Advisory Panel. The Stock Spikes.

    Amylyx Pharmaceuticals Stock Jumps After FDA Experts Back Drug

    Read full story

    FDA panel backs much-debated ALS drug in rare second review

    Read full story

    The FDA Is Giving Amylyx Another Chance on Its ALS Drug. What to Expect.

    Amylyx Pharma Falls 20%, FDA Expresses Concerns in Briefing Document About Sclerosis Drug

    Amylyx Pharmaceuticals Shares Down 30% After FDA Posts Briefing Documents

    Read full story

    Yes, the S&P 500 is climbing, but this is not yet a bull market

    Amylyx Shares Rally Premarket on FDA AdCom Meeting Plans >AMLX

    Read full story

    Don’t be tricked by any swift rallies in the S&P 500 — this is still a bear market

    Amylyx Pharma Shares Rise 15%, But Still Down 40% in Last 3 Months

    Amylyx Pharma Shares Rise 6% After Health Canada Approves Albrioza

    Amylyx says FDA decision date for ALS therapy is now in September; shares jump

    Shares of Amylyx Pharmaceuticals Inc. Inc. soared 21.6% in premarket trading on Friday after the company said U.S. regulators extended the review time for its experimental amyotrophic lateral sclerosis treatment. The new ...

    Read full story

    FDA panel narrowly rejects experimental ALS drug from Amylyx Pharma

    Read full story

    FDA Advisors Narrowly Oppose Amylyx’s ALS Drug

    Read full story

    Amylyx Stock Plummets as FDA Raises Doubts Over ALS Drug. A Key Meeting Is Wednesday

    Read full story

    AN2 Therapeutics Will Trade Friday. Now There Are 2 March IPOs.

    Read full story

    The FDA Has a New Chief. Here Are 5 Key Decisions on Drugs to Watch.

    Read full story

    The IPO Market Remains Tough. Why There Is a Glimmer of Hope.

    Read full story

    Yoshitsu’s IPO Takes the Lead for the Top Pop in 2022

    Read full story

    TPG Valued at $10.4 Billion After Public Debut

    Amylyx (AMLX) Up 51% After FDA Committee Endorses ALS Drug

    The FDA's PCNSDAC recommends granting marketing approval to Amylyx's (AMLX) oral drug, which slows the progression of ALS.

    on Zacks.com

    Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday

    on Benzinga.com

    This Is What Whales Are Betting On Amylyx Pharma

    on Benzinga.com

    US Stocks Flat, Crude Oil Rises 2%

    on Benzinga.com

    4 Analysts Have This to Say About Amylyx Pharma

    on Benzinga.com

    Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session

    on Benzinga.com

    US Stocks Turn Higher, Nasdaq Jumps 100 Points

    on Benzinga.com

    Amylyx (NASDAQ:AMLX) Jumps on Backing for ALS Treatment from FDA Advisory Committee

    Shares of clinical-stage biotechnology company Amylyx Pharmaceuticals (NASDAQ:AMLX) are up today after its Amyotrophic Lateral Sclerosis (ALS) treatment AMX0035 received favorable votes (7:2) from the U.S. Food and Drug Ad...

    on TipRanks.com

    Why Amylyx Pharmaceuticals Stock Is on Fire Today

    on Motley Fool

    AeroVironment, Snap And Some Other Big Stocks Moving Higher On Thursday

    on Benzinga.com

    After Initial Skepticism FDA's Adcomm Backs Amylyx's Amyotrophic Lateral Sclerosis Hopeful

    on Benzinga.com

    AAPL Stock Alert: 13 Takeaways From the Latest Apple Event 2022

    on InvestorPlace.com

    Dow Drops 100 Points; US Jobless Claims Fall Further Last Week

    on Benzinga.com

    Why Is Amylyx Pharmaceuticals (AMLX) Stock Up 70% Today?

    on InvestorPlace.com

    TipRanks Thurs PreMarket Update! AEO Pauses Dividend, GME Reports, AMLX Soars on FDA Nod + More!

    TipRanks Pre Market News! Today's Daily Stock Market Preview – Thursday September 8th 2022 Watch the TipRanks premarket news and stay up to date on stock market news before the market opens. We touch on earnings reports, t...

    on TipRanks.com

    FDA Again Highlights Lacking Data From Amylyx's Amyotrophic Lateral Sclerosis Candidate

    on Benzinga.com

    Why PolyPid Dipped Over 73%; Here Are 60 Biggest Movers From Friday

    on Benzinga.com

    Amylyx Pharma Whale Trades For September 01

    on Benzinga.com

    Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know

    on Benzinga.com

    Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), BioMarin Pharmaceutical (BMRN) and DENTSPLY SIRONA (XRAY)

    Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amylyx Pharmaceuticals Inc (AMLX – Research Report), BioMarin Pharmaceutical (BMRN – Research Report) and DENTSPLY SIRONA (XR...

    on TipRanks.com

    Amylyx Pharmaceuticals Inc.

    Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which provides disease-modifying solutions for neurodegenerative diseases. The firm focuses on streamlined clinical development and drug discovery. It specializes in developing a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases that target the neuroinflammation and nerve cell death that characterize these disorders. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.